FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056633229> ?p ?o ?g. }

• W2056633229 endingPage "208" @default.
• W2056633229 startingPage "203" @default.
• W2056633229 abstract "The Study for Monitoring Antimicrobial Resistance Trends (SMART) has tracked the in vitro activity of ertapenem and comparators against aerobic gram-negative bacteria from intra-abdominal infections since 2002. This report describes the epidemiology and susceptibility for clinical isolates associated with appendicitis, collected from 2008 to 2010.A total of 1,720 gram-negative bacilli were collected from patients with appendicitis in 122 hospitals in 39 countries worldwide; of these, 23% of isolates were from pediatric patients (≤ 17 years old). Minimum inhibitory concentrations (MICs) and extended-spectrum β-lactamase (ESBL) phenotypes were determined by broth microdilution and interpreted using Clinical and Laboratory Standards Institute guidelines.The global ESBL-positive rate was 16.3%, ranging from 2.2% for Proteus mirabilis to 16.6% for Escherichia coli and 20.1% for Klebsiella pneumoniae. The ESBL-positive rates differed by age group (17.7% in adults vs. 11.4% in children) and by geographic region, with significantly higher rates in Asia/Pacific (28.0%) and significantly lower rates in North America (9.1%), Africa/Middle East (4.8%), and Europe (4.4%). Amikacin, imipenem-cilastatin, piperacillin-tazobactam, and ertapenem were the most active of the tested agents against aerobic gram-negative appendicitis pathogens across pediatric and adult age groups and across geographic regions, including ESBL-positive isolates. Cefepime and ceftazidime were active against ≥ 90% of global pediatric isolates. E. coli, by far the most frequently isolated species (68% in adults and 75% in pediatric patients), was significantly less susceptible in adults than in pediatric patients (p<0.05; Fisher exact test) to all tested agents except amikacin, ertapenem, imipenem-cilastatin, piperacillin-tazobactam, and ampicillin-sulbactam (with the latter showing low activity in both age groups).These in vitro data suggest that amikacin, imipenem-cilastatin, piperacillin-tazobactam, and ertapenem would perform well against aerobic gram-negative bacilli associated with appendicitis in both adults and children, especially in regions with high rates of ESBL-positive E. coli." @default.
• W2056633229 created "2016-06-24" @default.
• W2056633229 creator A5017159626 @default.
• W2056633229 creator A5033454548 @default.
• W2056633229 creator A5046750212 @default.
• W2056633229 creator A5062847775 @default.
• W2056633229 creator A5063899317 @default.
• W2056633229 creator A5074503214 @default.
• W2056633229 date "2013-04-01" @default.
• W2056633229 modified "2023-10-03" @default.
• W2056633229 title "Epidemiology and Susceptibility of Gram-Negative Appendicitis Pathogens: SMART 2008–2010" @default.
• W2056633229 cites W1991721421 @default.
• W2056633229 cites W2027170606 @default.
• W2056633229 cites W2122823183 @default.
• W2056633229 cites W2140780207 @default.
• W2056633229 cites W2167112306 @default.
• W2056633229 cites W4246236965 @default.
• W2056633229 doi "https://doi.org/10.1089/sur.2012.034" @default.
• W2056633229 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23540793" @default.
• W2056633229 hasPublicationYear "2013" @default.
• W2056633229 type Work @default.
• W2056633229 sameAs 2056633229 @default.
• W2056633229 citedByCount "28" @default.
• W2056633229 countsByYear W20566332292013 @default.
• W2056633229 countsByYear W20566332292014 @default.
• W2056633229 countsByYear W20566332292015 @default.
• W2056633229 countsByYear W20566332292016 @default.
• W2056633229 countsByYear W20566332292017 @default.
• W2056633229 countsByYear W20566332292018 @default.
• W2056633229 countsByYear W20566332292019 @default.
• W2056633229 countsByYear W20566332292020 @default.
• W2056633229 countsByYear W20566332292021 @default.
• W2056633229 countsByYear W20566332292023 @default.
• W2056633229 crossrefType "journal-article" @default.
• W2056633229 hasAuthorship W2056633229A5017159626 @default.
• W2056633229 hasAuthorship W2056633229A5033454548 @default.
• W2056633229 hasAuthorship W2056633229A5046750212 @default.
• W2056633229 hasAuthorship W2056633229A5062847775 @default.
• W2056633229 hasAuthorship W2056633229A5063899317 @default.
• W2056633229 hasAuthorship W2056633229A5074503214 @default.
• W2056633229 hasConcept C107130276 @default.
• W2056633229 hasConcept C126322002 @default.
• W2056633229 hasConcept C176947019 @default.
• W2056633229 hasConcept C2777050379 @default.
• W2056633229 hasConcept C2777427914 @default.
• W2056633229 hasConcept C2777637488 @default.
• W2056633229 hasConcept C2778039505 @default.
• W2056633229 hasConcept C2778193466 @default.
• W2056633229 hasConcept C2778266534 @default.
• W2056633229 hasConcept C2778368673 @default.
• W2056633229 hasConcept C2779489039 @default.
• W2056633229 hasConcept C2779631663 @default.
• W2056633229 hasConcept C2780950330 @default.
• W2056633229 hasConcept C4937899 @default.
• W2056633229 hasConcept C501593827 @default.
• W2056633229 hasConcept C523546767 @default.
• W2056633229 hasConcept C54355233 @default.
• W2056633229 hasConcept C71924100 @default.
• W2056633229 hasConcept C86803240 @default.
• W2056633229 hasConcept C89423630 @default.
• W2056633229 hasConcept C94665300 @default.
• W2056633229 hasConceptScore W2056633229C107130276 @default.
• W2056633229 hasConceptScore W2056633229C126322002 @default.
• W2056633229 hasConceptScore W2056633229C176947019 @default.
• W2056633229 hasConceptScore W2056633229C2777050379 @default.
• W2056633229 hasConceptScore W2056633229C2777427914 @default.
• W2056633229 hasConceptScore W2056633229C2777637488 @default.
• W2056633229 hasConceptScore W2056633229C2778039505 @default.
• W2056633229 hasConceptScore W2056633229C2778193466 @default.
• W2056633229 hasConceptScore W2056633229C2778266534 @default.
• W2056633229 hasConceptScore W2056633229C2778368673 @default.
• W2056633229 hasConceptScore W2056633229C2779489039 @default.
• W2056633229 hasConceptScore W2056633229C2779631663 @default.
• W2056633229 hasConceptScore W2056633229C2780950330 @default.
• W2056633229 hasConceptScore W2056633229C4937899 @default.
• W2056633229 hasConceptScore W2056633229C501593827 @default.
• W2056633229 hasConceptScore W2056633229C523546767 @default.
• W2056633229 hasConceptScore W2056633229C54355233 @default.
• W2056633229 hasConceptScore W2056633229C71924100 @default.
• W2056633229 hasConceptScore W2056633229C86803240 @default.
• W2056633229 hasConceptScore W2056633229C89423630 @default.
• W2056633229 hasConceptScore W2056633229C94665300 @default.
• W2056633229 hasIssue "2" @default.
• W2056633229 hasLocation W20566332291 @default.
• W2056633229 hasLocation W20566332292 @default.
• W2056633229 hasOpenAccess W2056633229 @default.
• W2056633229 hasPrimaryLocation W20566332291 @default.
• W2056633229 hasRelatedWork W2056633229 @default.
• W2056633229 hasRelatedWork W2092174507 @default.
• W2056633229 hasRelatedWork W2118166742 @default.
• W2056633229 hasRelatedWork W2138523916 @default.
• W2056633229 hasRelatedWork W2143324329 @default.
• W2056633229 hasRelatedWork W2357545671 @default.
• W2056633229 hasRelatedWork W2362848007 @default.
• W2056633229 hasRelatedWork W2370576291 @default.
• W2056633229 hasRelatedWork W2919702677 @default.
• W2056633229 hasRelatedWork W59447253 @default.
• W2056633229 hasVolume "14" @default.

• next